Today's Top SOA Links
From the Wires
MagForce starts research project with University of Bremen
By: Marketwired .
Jan. 31, 2013 04:08 AM
BERLIN, GERMANY -- (Marketwire) -- 01/31/13 --
MagForce AG / MagForce starts research project with University of Bremen . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
* Project to develop magnetic iron oxide particles with improved efficiency
* Agreement on funding by German Federal Ministry of Economics and Technology from the German Mittelstand innovation program "Zentrales Innovationsprogramm Mittelstand (ZIM)"
MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, today announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The novel particles will allow a more efficient treatment of abdominal cancers, such as prostate and pancreatic cancer. A more efficient magnetic fluid and a pilot manufacturing facility will result from the collaboration.
The project will receive funding from the German Mittelstand Innovation Program (ZIM) which is managed by the German Federal Ministry of Economics and Technology and will run for two years.
"We are excited to be working with Prof Dr Jorg Thöming, who is an internationally renowned expert in the area of process engineering, as a cooperation partner. This project is perfectly in-line with MagForce's new strategy to conduct early-stage research and development collaborations with academic institutions", commented Prof Dr Hoda Tawfik, COO and co- CEO of MagForce AG. "In August 2012, we temporarily put all internal early- stage research and development on hold to focus the Company's resources on establishing our NanoTherm® therapy in the market. This project gives us the opportunity to develop the next generation of NanoTherm® that will significantly improve the treatment of abdominal cancers." Prof Dr Jorg Thöming comments: "I am excited to start the collaboration in the nanotechnology area with MagForce, an innovative nanomedicine company. The exploitation of synergies between our scientists is very promising."
About MagForce AG
MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator are trademarks of MagForce AG in select countries. For more information, please visit www.magforce.com.
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward- looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
MagForce_Press Release_Jan 31, 2013: http://hugin.info/143761/R/1674480/545259.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE [HUG#1674480]
Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week